Vetoquinol SA (LON:0O1O)

Market Cap	705.81M -13.7%
Revenue (ttm)	458.59M -2.5%
Net Income	50.04M -2.3%
EPS	4.31 -0.8%
Shares Out	n/a
PE Ratio	14.11
Forward PE	14.30
Dividend	0.81 (1.31%)
Ex-Dividend Date	Jun 3, 2026

Volume	32
Open	71.00
Previous Close	72.10
Day's Range	71.00 - 71.00
52-Week Range	67.50 - 91.20
Beta	0.89
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,486
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0O1O

Financial Performance

In 2025, Vetoquinol's revenue was 525.69 million, a decrease of -2.51% compared to the previous year's 539.20 million. Earnings were 57.36 million, a decrease of -2.26%.

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 20, 2026

Data Sources Report a data error